

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **July 1, 2022** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the July 1, 2022 Updates for complete listings of products available by special authorization, step therapy/ special authorization, products with changes to criteria for coverage, added products, new established interchangeable groupings, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application and, as such, contains the most up-to-date information.

Insulin Pump Therapy Program termination on hold

It was previously announced, that effective August 1, 2022, the Government of Alberta will be terminating the Insulin Pump Therapy Program (IPTP) and make insulin pump therapy benefits available through the Alberta Health supplementary health benefit programs, such as Coverage for Seniors, Non-group Coverage and the low-income health benefit programs like Income Support and Assured Income for the Severely Handicapped (AISH).

On May 12, it was announced by the Minister of Health, Minister Copping, that the plan to terminate the IPTP on August 1, 2022, is on hold until Alberta Health does further consultation. Until further notice, the proposed changes to the IPTP have been paused.

Product supply shortages addressed for the Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Carbamazepine 20 mg/ml Oral Suspension (DIN 02367394) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 20, 2022**. The following grouping was removed from the Critical Supply Product List on **June 20, 2022**.

CARBAMAZEPINE

20 MG/ML ORAL SUSPENSION

00002367394	TARO-CARBAMAZEPINE	TAR	\$ 0.0764
00002194333	TEGRETOL	NOV	\$ 0.0856

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Glycopyrrolate 0.2 mg/ml Injection (DIN 02039508) manufactured by Sandoz Canada Inc., Glycopyrrolate 0.2 mg/ml Injection (DIN 02382857) manufactured by Omega Laboratories Limited will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **June 13, 2022**.

As of **June 13, 2022**, all claims for Glycopyrrolate 0.2 mg/ml Injection (DIN 02382857) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

continued next page

continued from previous page

Temporary benefit added to the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the unavailability of Robitussin Childrens Cough and Cold Oral Liquid (DIN 02044013) manufactured by Glaxosmithkline Consumer Healthcare, Benylin DM-D for Children Oral Syrup (DIN 01944746) manufactured by McNeil Consumer Healthcare will be considered a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*. This grouping was added to the Critical Supply Product List on **June 17, 2022**.

As of **June 13, 2022**, all claims for Benylin DM-D for Children Oral Syrup (DIN 01944746) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage for Apo-Amitriptyline 10 mg Tablet (DIN 02403137) manufactured by Apotex Inc. and Elavil 10 mg Tablet (DIN 00335053) manufactured by AA Pharma Inc., Mar-Amitriptyline 10 mg Tablet (DIN 02429861) manufactured by Marcan Pharmaceuticals Inc and pms-Amitriptyline 10 mg Tablet (DIN 00654523) manufactured by Pharmascience Inc were added as temporary benefits for the Alberta Drug Benefit List (ADBL).

Apotex Inc. has advised Alberta Blue Cross that the shortage for Apo-Amitriptyline 10 mg Tablet (DIN 02403137) has been resolved.

As a result, Mar-Amitriptyline 10 mg Tablet (DIN 02429861) and pms-Amitriptyline 10 mg Tablet (DIN 00654523) will no longer be considered temporary benefits for the *ADBL* after **July 21, 2022**. The above grouping was removed from the Critical Supply Product List on **June 21, 2022**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

